Previously, we reported that post-translational modifications (PTMs) of MAGI1, including S741 phosphorylation and K931 de-SUMOylation, both of which are regulated by p90RSK activation, lead to endothelial cell (EC) activation. However, roles for p90RSK and MAGI1-PTMs in regulating EC permeability remain unclear despite MAGI1 being a junctional molecule. Here, we show that thrombin (Thb)-induced EC permeability, detected by the electric cell-substrate impedance sensing (ECIS) based system, was decreased by overexpression of dominant negative p90RSK or a MAGI1-S741A phosphorylation mutant, but was accelerated by overexpression of p90RSK, siRNA-mediated knockdown of , or the MAGI1-K931R SUMOylation mutant. MAGI1 depletion also increased the mRNA and protein expression of the large tumor suppressor kinases 1 and 2 (LATS1/2), which inhibited YAP/TAZ activity and increased EC permeability. Because the endothelial barrier is a critical mediator of tumor hypoxia, we also evaluated the role of p90RSK activation in tumor vessel leakiness by using a relatively low dose of the p90RSK specific inhibitor, FMK-MEA. FMK-MEA significantly inhibited tumor vessel leakiness at a dose that does not affect morphology and growth of tumor vessels . These results provide novel insights into crucial roles for p90RSK-mediated MAGI1 PTMs and the Hippo pathway in EC permeability, as well as p90RSK activation in tumor vessel leakiness.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693647PMC
http://dx.doi.org/10.3389/fcvm.2020.542485DOI Listing

Publication Analysis

Top Keywords

p90rsk activation
12
tumor vessel
12
vessel leakiness
12
post-translational modifications
8
hippo pathway
8
activation tumor
8
p90rsk
7
tumor
6
permeability
5
magi1
5

Similar Publications

RSK1 and RSK2 as therapeutic targets: an up-to-date snapshot of emerging data.

Expert Opin Ther Targets

December 2024

Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.

Introduction: The four members of the p90 ribosomal S6 kinase (RSK) family are serine/threonine protein kinases, which are phosphorylated and activated by ERK1/2. RSK1/2/3 are further phosphorylated by PDK1. Receiving inputs from two major signaling pathways places RSK as a key signaling node in numerous pathologies.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple myeloma (MM) is a type of blood cancer marked by excessive production of plasma cells that release antibodies, and current research on treatments like Raddeanin A (RA) focuses mainly on solid tumors, leaving a gap in understanding its effects on MM specifically.
  • RA, derived from Anemone raddeana regel, shows promising anti-tumor effects, and this study explores how it may inhibit MM cell growth through network pharmacology and experimental methods, revealing significant interactions with the MAPK signaling pathway.
  • Experimental results demonstrate that RA effectively slows MM cell proliferation, induces apoptosis, alters mitochondrial function, and impacts the expression of key proteins involved in cell growth and survival, suggesting a powerful potential for RA as a treatment for multiple my
View Article and Find Full Text PDF

A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR.

Neoplasia

January 2025

Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32610, USA. Electronic address:

Article Synopsis
  • Oncogenic KRAS signaling is vital in pancreatic ductal adenocarcinoma (PDAC), and previous treatments targeting MEK and BCL-xL were ineffective due to amplified EGFR signaling in patients.
  • A new strategy using a triplet therapy involving trametinib (MEK inhibitor), DT2216 (BCL-xL degrader), and afatinib (EGFR inhibitor) showed improved results in killing PDAC cells both in lab tests and in mouse models.
  • The combination produced significantly better tumor growth reduction compared to double treatments and highlighted EGFR's role, suggesting this triplet approach warrants clinical testing for PDAC patients.
View Article and Find Full Text PDF
Article Synopsis
  • - KRAS mutations are prevalent in lung adenocarcinoma among Black Americans, leading to the exploration of Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) as potential therapies to disrupt hyperactive G-protein signaling caused by mutated RAS proteins.
  • - Among 17 PCAIs tested, NSL-YHJ-2-27 and NSL-YHJ-2-46 demonstrated significant potency in affecting KRAS-mutated lung cancer cells, with EC50 values of 2.7 μM and 3.3 μM, and notable changes in MAPK pathway enzyme phosphorylation.
  • - Treatment with these PCAIs led to decreased levels of key G-proteins linked to cell migration
View Article and Find Full Text PDF
Article Synopsis
  • * Punicalagin (PUN), an extract from pomegranate peel, was discovered to increase AhR expression and activate its signaling pathways, which play a role in inflammatory macrophages.
  • * PUN's effects depended on specific kinase pathways and contributed to reducing inflammation and enhancing macrophage survival against bacterial infections.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!